Connect with us

Australia

Trigg Mining managing director shows faith in SOP strategy with on-market purchase

Trigg Mining Ltd (ASX:TMG) managing director Keren Paterson has demonstrated her confidence in the companys sulphate of potash (SOP) strategy with an on-market share purchase.

On June 2, Paterson acquired 52,000 shares in a direct interest.

She now holds 52,000 fully paid ordinary shares in that direct interest and another 1.45 million loan shares in the same interest, which were acquired under a Loan Funded Plan.

The MD also holds 2.498 million shares in an indirect interest.

Shares last traded at 8 cents and since the close on April 1 have traded in the range from 2 cents to 8.7 cents.

Road sealing boost[hhmc]
Last week Trigg received an infrastructure boost for its Lake Throssell SOP Project in WA with a joint State and Federal government program to seal a 41-kilometre section of the Great Central Road.

The road is a key arterial route that runs from Leonora and Laverton towards Trigg's high-grade project and the $20 million road sealing contract will assist in future pro..

Trigg Mining Ltd (ASX:TMG) managing director Keren Paterson has demonstrated her confidence in the companys sulphate of potash (SOP) strategy with an on-market share purchase.

On June 2, Paterson acquired 52,000 shares in a direct interest.

She now holds 52,000 fully paid ordinary shares in that direct interest and another 1.45 million loan shares in the same interest, which were acquired under a Loan Funded Plan.

The MD also holds 2.498 million shares in an indirect interest.

Shares last traded at 8 cents and since the close on April 1 have traded in the range from 2 cents to 8.7 cents.

Road sealing boost


Last week Trigg received an infrastructure boost for its Lake Throssell SOP Project in WA with a joint State and Federal government program to seal a 41-kilometre section of the Great Central Road.

The road is a key arterial route that runs from Leonora and Laverton towards Trigg's high-grade project and the $20 million road sealing contract will assist in future project development.

This work is expected to improve project access and future logistics in terms of the transport of people, equipment, materials and product to and from the project.

Travel restrictions eased


The WA Government also announced a further phased lifting of intrastate travel restrictions which is expected to clear the way for the resumption of field activities and for the companys maiden exploration aircore drilling program to begin next quarter.

SOP targets defined


Read More – Source

Continue Reading

Australia

Paradigm Biopharmaceuticals set to release results of FDAs IND expanded access program for Zilosul osteoarthritis treatment

Paradigm Biopharmaceuticals Ltd (ASX:PAR) expects to release results for its Zilosul treatment for osteoarthritis under the US Food and Drug Administration's (FDA) Investigational New Drug expanded access program (EAP) in early August.

The results will include a video detailing the patients under the EAP and their previous struggles with osteoarthritis caused by joint issues during their professional NFL careers and will highlight outcomes and results after completion of the Zilosul ® treatment program.

All patients have completed their follow-up screenings and the EAP database has been locked for data cleaning and preparation of patient results.

The company said it remained focused on its IND submission to the FDA for the remainder of 2020.

The Paradigm team and its consultants continue to compile the necessary information and data for submission towards the end of the fourth quarter.

Shares have been as much as 13.5% higher to $3.21.

TGA submission[hhmc]
Paradigm Biopharma..

Paradigm Biopharmaceuticals Ltd (ASX:PAR) expects to release results for its Zilosul treatment for osteoarthritis under the US Food and Drug Administration's (FDA) Investigational New Drug expanded access program (EAP) in early August.

The results will include a video detailing the patients under the EAP and their previous struggles with osteoarthritis caused by joint issues during their professional NFL careers and will highlight outcomes and results after completion of the Zilosul ® treatment program.

All patients have completed their follow-up screenings and the EAP database has been locked for data cleaning and preparation of patient results.

The company said it remained focused on its IND submission to the FDA for the remainder of 2020.

The Paradigm team and its consultants continue to compile the necessary information and data for submission towards the end of the fourth quarter.

Shares have been as much as 13.5% higher to $3.21.

TGA submission


Paradigm Biopharmaceuticals is continuing to prepare information requested by the Therapeutic Goods Administration (TGA) for the next stage of submission for the Provisional Approval determination for the use of Zilosul in the treatment of osteoarthritis.

It will update the market on the progress of this process in the fourth quarter this year.

There is additional new data on 67 patients treated under the Special Access Scheme (SAS) program and the company expects to report on 35 patients in the third quarter with the remaining patient data expected to be available in early fourth quarter this year.

The data will be presented, using the same endpoints and product identified for Paradigms Phase 3 trials. This will take the total number of SAS patients reported on with the proposed Phase 3 endpoints to over 100 patients.

Commercial research deal


Paradigm Biopharmaceuticals is in the process of finalising a commercial research agreement with an unnamed Australian university.

The research program will investigate the safety and efficacy of injectable Pentosan Polysulfate Sulfate (iPPS) in a viral-induced respiratory disease model.

Additional details on this agreement will be released to the market once this has been completed.

Proposed Phase III


The primary and secondary endpoints for Paradigms proposed Phase 3 trial will be

➢ Reduced WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain from baseline; and

➢ Improved Patient Global Impression of Change (PGIC).

Paradigm plans to conduct two randomized controlled Phase 3 clinical trials consisting of 750 patients in the first Phase 3 trial and 400 patients in the second Phase 3 trial (confirmatory study).

MPS-1


Paradigm expects to receive notification from the Ethics Committee on its MPS-1 (Mucopolysaccharidosis) clinical program in the current quarter.

It is also expecting feRead More – Source

Continue Reading

Australia

Nexus Minerals advances gold strategy with Pinnacles JV feasibility study and Wallbrook drilling

Nexus Minerals Ltd (ASX:NXM) is progressing its gold strategy centred on WAs Eastern Goldfields with a feasibility study underway on the Pinnacles joint venture (JV) project and reverse circulation (RC) drilling to start this month at the Wallbrook project.

The JV with Saracen Mineral Holdings Limited (ASX:SAR) has started work on the Pinnacles feasibility study following positive results from an independent scoping study, which paves the way for the project to advance rapidly.

Study work[hhmc]
As part of the study, Nexus is determining the feasibility of the open cut potential of the Pinnacles East gold resource area with deeper mineralisation to be considered as a potential underground operation.

The study will incorporate additional resource definition drilling, geotechnical drilling, environmental studies and metallurgical test-work along with other key assessments and permitting.

Pinnacles JV project location.

In association with consultants, the company is set to complete th..

Nexus Minerals Ltd (ASX:NXM) is progressing its gold strategy centred on WAs Eastern Goldfields with a feasibility study underway on the Pinnacles joint venture (JV) project and reverse circulation (RC) drilling to start this month at the Wallbrook project.

The JV with Saracen Mineral Holdings Limited (ASX:SAR) has started work on the Pinnacles feasibility study following positive results from an independent scoping study, which paves the way for the project to advance rapidly.

Study work


As part of the study, Nexus is determining the feasibility of the open cut potential of the Pinnacles East gold resource area with deeper mineralisation to be considered as a potential underground operation.

The study will incorporate additional resource definition drilling, geotechnical drilling, environmental studies and metallurgical test-work along with other key assessments and permitting.

Pinnacles JV project location.

In association with consultants, the company is set to complete the following feasibility study components with results expected in late 2020:

  • Reverse circulation (RC) and diamond drilling to begin in August;
  • Geotechnical studies commenced;
  • Metallurgical studies commenced;
  • Environmental studies commenced; and
  • Mining Proposal preparation underway.

Nexus remains in the process of conducting preliminary confidential discussions to secure funding for the start of production.

These current discussions focus on working towards a gold repurchase and funding agreement to provide funding of approximately $5 million.

Wallbrook drilling


An exploration RC drilling program is set to begRead More – Source

Continue Reading

Australia

eSense-Lab achieves key milestones that validate commercialisation model for terpenes

eSense-Lab Ltd (ASX:ESE) continues to achieve strategic and operational milestones as it progresses a commercialisation strategy for evidence-based terpene product development for medicinal and wellness uses.

Signed contracts and partnership agreements during the first half of 2020 have positioned the company to increase sales and revenue growth as it demonstrates the broad range of applications for its terpenes.

Contracts and JVs[hhmc]
In this period eSense has secured three agreements to supply its unique terpenes across multiple revenue-generating markets.

An exclusive sales agency contract has also been executed targeting A$10 million of product sales in the lucrative US market over five years.

eSense has signed joint venture agreements with initial orders anticipated to provide revenue of approximately A$950,000 to the company and it is working towards more large revenue joint-venture opportunities.

Establishing joint ventures for mutual development of products with different..

eSense-Lab Ltd (ASX:ESE) continues to achieve strategic and operational milestones as it progresses a commercialisation strategy for evidence-based terpene product development for medicinal and wellness uses.

Signed contracts and partnership agreements during the first half of 2020 have positioned the company to increase sales and revenue growth as it demonstrates the broad range of applications for its terpenes.

Contracts and JVs


In this period eSense has secured three agreements to supply its unique terpenes across multiple revenue-generating markets.

An exclusive sales agency contract has also been executed targeting A$10 million of product sales in the lucrative US market over five years.

eSense has signed joint venture agreements with initial orders anticipated to provide revenue of approximately A$950,000 to the company and it is working towards more large revenue joint-venture opportunities.

Establishing joint ventures for mutual development of products with different partners allows the company to position itself across multiple revenue-generating markets.

Post-COVID applications


eSense CEO Itzik Mizrahi said: “We have worked hard to achieve a number of strategic and operational milestones over the last four months and are proud of the progress to date.

"In addition to their therapeutic and wellness benefits, our terpenes have exciting possible applications in a post-COVID world and are focused on being well-positioned to service this growing market.

"We are hard at work continuing to pursue more joint-venture opportunities and researching further potential applications of our technology.”

Leveraging core technology


The company has also made important changes to its leadership team and business strategy as it seeks to best leverage its core terpenes technology for revenue growth.

Under this guidance eSense has signed agreements across a range of markets:

  • SeaLaria (LOI) – Therepeutic skin creams and sanitiser;
  • ANC – Skin care, hair care and hand sanitiser;
  • Wise Wine – Hand and surface sanitisers; and
  • Blue Science – Hand and surface sanitisers.

This approach is favoured by eSense as it reduces the upfront capital expenditure required to expand global reach and significantly reduces costs associated with sales and distribution.

Since inception of this strategy, the company has been able to leverage the distribution channels of its partners to gain access to four major global markets – Israel/Middle East, Australia, China and the US.

Key Blue Science agreement


A key agreement in the commercialisation strategy was signed this month through an exclusive Sales Agency Agreement with Blue Science Solutions Inc to expand into the worlds largest consumer market for terpenes-based products, the United States.

Blue Science is an established US-based company that delivers non-toxic cleaning and disinfecting solutions across a variety of industries.

Access to IBM network


A crucial aspect of this new partnership for eSense is access to the IBM Rapid Supplier Connect Network.

This network makes it possible for buyers and suppliers, including non-traditional suppliers joining the fight to help keep hospitals and key support organisations ready, to quickly find each other, accelerate verification and onboarding processes, and gain near real-time insights into inventories of life-saving equipment.

Other benefits for eSense include:

Continue Reading

Trending